Latest Insider Transactions at Arcturus Therapeutics Holdings Inc. (ARCT)
This section provides a real-time view of insider transactions for Arcturus Therapeutics Holdings Inc. (ARCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcturus Therapeutics Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcturus Therapeutics Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
12,000
-2.68%
|
$240,000
$20.76 P/Share
|
|
Jun 14
2024
|
Peter C Farrell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+5.32%
|
-
|
|
Jun 14
2024
|
James F Barlow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+19.25%
|
-
|
|
Jun 14
2024
|
Magda Marquet Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
John Markels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
Edward W Holmes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
Jing L. Marantz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 12
2024
|
Andy Sassine Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-18.48%
|
$1,600,000
$32.03 P/Share
|
|
Jun 05
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
114
-0.03%
|
$5,130
$45.0 P/Share
|
|
Jun 03
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
26,000
-5.49%
|
$1,040,000
$40.01 P/Share
|
|
Mar 25
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
17,435
-3.55%
|
$610,225
$35.02 P/Share
|
|
Mar 19
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
8,565
-1.71%
|
$299,775
$35.01 P/Share
|
|
Nov 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.99%
|
$90,000
$18.72 P/Share
|
|
Oct 02
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.98%
|
$125,000
$25.61 P/Share
|
|
Sep 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.97%
|
$155,000
$31.45 P/Share
|
|
Aug 15
2023
|
Andy Sassine Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,223
+0.45%
|
$20,791
$17.37 P/Share
|
|
Aug 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.96%
|
$170,000
$34.91 P/Share
|
|
Jul 14
2023
|
Keith C Kummerfeld Officer |
SELL
Open market or private sale
|
Direct |
6,968
-88.0%
|
$243,880
$35.0 P/Share
|
|
Jul 14
2023
|
Keith C Kummerfeld Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,968
+24.67%
|
$62,712
$9.38 P/Share
|
|
Jul 14
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
25,000
-4.59%
|
$875,000
$35.01 P/Share
|
|
Jul 03
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.91%
|
$140,000
$28.75 P/Share
|
|
Jun 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.9%
|
$135,000
$27.16 P/Share
|
|
May 11
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
7,925
-1.41%
|
$237,750
$30.24 P/Share
|
|
May 10
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
17,075
-2.95%
|
$512,250
$30.0 P/Share
|
|
May 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.86%
|
$125,000
$25.93 P/Share
|
|
Apr 18
2023
|
Keith C Kummerfeld Officer |
SELL
Open market or private sale
|
Direct |
6,968
-88.0%
|
$195,104
$28.18 P/Share
|
|
Apr 18
2023
|
Keith C Kummerfeld Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,968
+30.19%
|
$62,712
$9.38 P/Share
|
|
Apr 03
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.85%
|
$125,000
$25.38 P/Share
|
|
Mar 06
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.84%
|
$80,000
$16.07 P/Share
|
|
Dec 15
2022
|
Magda Marquet Director |
BUY
Open market or private purchase
|
Indirect |
2,222
+8.18%
|
$39,996
$18.0 P/Share
|
|
Nov 23
2022
|
Joseph E Payne President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.34%
|
$80,000
$16.51 P/Share
|
|
Aug 15
2022
|
Andy Sassine Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,068
+0.4%
|
$19,224
$18.42 P/Share
|
|
Jan 04
2022
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
8,100
-1.34%
|
$324,000
$40.0 P/Share
|
|
Dec 16
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
3,633
-0.6%
|
$145,320
$40.0 P/Share
|
|
Dec 08
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
6,367
-1.04%
|
$254,680
$40.0 P/Share
|
|
Nov 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.61%
|
$440,000
$44.41 P/Share
|
|
Oct 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.58%
|
$440,000
$44.36 P/Share
|
|
Sep 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.56%
|
$550,000
$55.86 P/Share
|
|
Aug 11
2021
|
Ultragenyx Pharmaceutical Inc. Director |
SELL
Open market or private sale
|
Direct |
75,000
-5.08%
|
$3,375,000
$45.83 P/Share
|
|
Aug 10
2021
|
Ultragenyx Pharmaceutical Inc. Director |
SELL
Open market or private sale
|
Direct |
725,000
-32.95%
|
$39,875,000
$55.44 P/Share
|
|
Aug 03
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.53%
|
$400,000
$40.07 P/Share
|
|
Apr 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.51%
|
$420,000
$42.95 P/Share
|
|
Mar 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.49%
|
$540,000
$54.23 P/Share
|
|
Feb 01
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.47%
|
$750,000
$75.31 P/Share
|
|
Jan 04
2021
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.44%
|
$460,000
$46.4 P/Share
|
|
Dec 09
2020
|
Ultragenyx Pharmaceutical Inc. Director |
SELL
Open market or private sale
|
Direct |
357,745
-13.99%
|
$33,628,030
$94.97 P/Share
|
|
Dec 08
2020
|
Ultragenyx Pharmaceutical Inc. Director |
SELL
Open market or private sale
|
Direct |
442,255
-14.74%
|
$46,436,775
$105.54 P/Share
|
|
Dec 01
2020
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.42%
|
$960,000
$96.19 P/Share
|
|
Nov 02
2020
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.4%
|
$550,000
$55.28 P/Share
|
|
Oct 01
2020
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
10,000
-1.38%
|
$420,000
$42.83 P/Share
|